Key result
Randomized controlled trials for non-communicable diseases conducted in middle-income countries were significantly less likely to have high study validity than those in high-income countries (OR 0.444).
Systematic Review (n=1,177)
Effect estimate: OR 0.444 (95% CI 0.251-0.786)
p-value: p=0.005
There is a significant gap in the quantity and quality of clinical research for non-communicable diseases in less developed countries compared to high-income countries.
Highlights validity gaps in middle-income NCD trials; leaves open how best to strengthen research capacity.
Research is crucial to implement evidence-based health interventions for control of non-communicable diseases (NCDs). This study aims to assess main features of randomized controlled trials (RCTs) for control of NCDs, and to identify gaps in clinical research on NCDs between high-income and less developed countries. The study included 1177 RCTs in 82 Cochrane Systematic reviews (CSRs) and evaluated interventions for adults with hypertension, diabetes, stroke, or heart diseases. Multivariate logistic regression analyses were conducted to explore factors associated with risk of bias in included RCTs. We found that 78.2% of RCTs of interventions for major NCDs recruited patients in high-income countries. The number of RCTs included in the CSRs was increasing over time, and the increasing speed was more noticeable for RCTs conducted in middle-income countries. RCTs conducted in less developed countries tended to be more recently published, less likely to be published in English, with smaller sample sizes, and at a higher risk of bias. In conclusion, there is still a lack of research evidence for control of NCDs in less developed countries. To brace for rising NCDs and avoid waste of scarce research resources, not only more but also higher quality clinical trials are required in low-and-middle-income countries.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2015) conducted a systematic review in Non-communicable diseases (hypertension, diabetes, stroke, heart diseases) (n=1,177). RCTs conducted in middle-income countries vs. RCTs conducted in high-income countries was evaluated on High study validity (low risk of bias in ≥4 of 5 items) (OR 0.444, 95% CI 0.251-0.786, p=0.005). Randomized controlled trials for non-communicable diseases conducted in middle-income countries were significantly less likely to have high study validity than those in high-income countries (OR 0.444).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: